Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 14,331 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of Genelux stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $3.53, for a total transaction of $50,588.43. Following the sale, the insider now owns 1,285,794 shares of the company’s stock, valued at approximately $4,538,852.82. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Stock Down 0.9 %

Shares of Genelux stock opened at $3.45 on Thursday. The firm’s 50 day moving average price is $5.86 and its 200-day moving average price is $10.95. Genelux Co. has a 52-week low of $3.26 and a 52-week high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). On average, equities research analysts forecast that Genelux Co. will post -0.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GNLX has been the topic of a number of research reports. HC Wainwright cut their target price on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Benchmark reissued a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research report on Wednesday, April 3rd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GNLX. Woodward Diversified Capital LLC grew its position in shares of Genelux by 2,326.2% in the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after buying an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. grew its position in Genelux by 1,660.1% during the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock worth $24,025,000 after purchasing an additional 925,258 shares during the last quarter. Provident Wealth Management LLC purchased a new stake in Genelux during the 3rd quarter worth approximately $8,211,000. AMG National Trust Bank purchased a new stake in Genelux during the 3rd quarter worth approximately $1,233,000. Finally, Bank of New York Mellon Corp grew its position in Genelux by 476.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock worth $1,321,000 after purchasing an additional 44,584 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.